The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets

被引:47
作者
Abramson, Hanley N. [1 ]
机构
[1] Wayne State Univ, Dept Pharmaceut Sci, 259 Mack Ave, Detroit, MI 48201 USA
关键词
Bcl-2; inhibitors; Epigenetics; Immunomodulators; Nuclear export inhibitors; Ubiquitinatione-proteasome system; HISTONE DEACETYLASE INHIBITORS; NUCLEAR EXPORT; PROTEASOME INHIBITOR; PLUS BORTEZOMIB; DNA-DAMAGE; SELECTIVE-INHIBITION; ANTITUMOR-ACTIVITY; DOSE-ESCALATION; SINGLE-AGENT; PHASE-I;
D O I
10.1016/j.clml.2018.06.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation, has changed dramatically in the past 20 years because 3 new classes of small molecule drugs (arbitrarily defined as having a molecular weight of < 900 kDa)-immunomodulators, proteasome inhibitors, and histone deacetylase blockers-have been introduced for the disease. Therapeutic options for MM expanded further in 2015 when 2 new monoclonal antibodies (daratumumab and elotuzumab) were approved by the Food and Drug Administration for MM. Although MM remains incurable, the cumulative effect of these advances has resulted in a near-doubling of the 5-year survival rate since the late 1980s. Despite these advances, therapy for MM continues to pose substantial challenges because resistance to therapy frequently develops, and relapse and recurrence are all too common. The present review focused on the pipeline for new small molecules in various stages of development and their associated cellular targets. In addition to newer versions of alkylators, immunomodulators, proteasome inhibitors, and histone deacetylase inhibitors, the present review considered the prospects for adding new classes of small molecules to the MM armamentarium, which offer the potential for oral efficacy, relative simplicity of preparation, and prospects for improvement in the cost-to-benefit ratio. Included are agents that affect myeloma epigenetics and the ubiquitinationeproteasome system and the unfolded protein response, apoptotic mechanisms, chromosomal abnormalities, nuclear protein transport, and various kinases involved in cellular signaling pathways. (C) 2018 The Author. Published by Elsevier Inc.
引用
收藏
页码:611 / 627
页数:17
相关论文
共 120 条
[81]   Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors [J].
Pei, XY ;
Dai, Y ;
Grant, S .
CLINICAL CANCER RESEARCH, 2004, 10 (11) :3839-3852
[82]  
Perel Galina, 2016, P T, V41, P303
[83]   Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines [J].
Pinkerneil, Maria ;
Hoffmann, Michele J. ;
Kohlhof, Hella ;
Schulz, Wolfgang A. ;
Niegisch, Guenter .
TARGETED ONCOLOGY, 2016, 11 (06) :783-798
[84]   Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma [J].
Poenisch, Wolfram ;
Holzvogt, Bruno ;
Ploetze, Madlen ;
Andrea, Marc ;
Bourgeois, Malvina ;
Heyn, Simone ;
Zehrfeld, Thomas ;
Hammerschmidt, Doreen ;
Schwarz, Maik ;
Edelmann, Thomas ;
Becker, Cornelia ;
Hoffmann, Franz Albert ;
Schwarzer, Andreas ;
Kreibich, Ute ;
Gutsche, Kerstin ;
Reifenrath, Kolja ;
Winkelmann, Cornelia ;
Krahl, Rainer ;
Remane, Yvonne ;
Hennig, Evelin ;
Schliwa, Thomas ;
Lindner, Tom ;
Kaiser, Thorsten ;
Vucinic, Vladan ;
Behre, Gerhard ;
Niederwieser, Dietger .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (11) :1947-1956
[85]   Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies [J].
Prabhu, Varun V. ;
Talekar, Mala K. ;
Lulla, Amriti R. ;
Kline, C. Leah B. ;
Zhou, Lanlan ;
Hall, Junior ;
Van den Heuvel, A. Pieter J. ;
Dicker, David T. ;
Babar, Jawad ;
Grupp, Stephan A. ;
Garnett, Mathew J. ;
McDermott, Ultan ;
Benes, Cyril H. ;
Pu, Jeffrey J. ;
Claxton, David F. ;
Khan, Nadia ;
Oster, Wolfgang ;
Allen, Joshua E. ;
El-Deiry, Wafik S. .
CELL CYCLE, 2018, 17 (04) :468-478
[86]  
Raedler Lisa, 2015, Am Health Drug Benefits, V8, P135
[87]   A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells [J].
Ray, Arghya ;
Ravillah, Durgadevi ;
Das, Deepika S. ;
Song, Yan ;
Nordstrom, Eva ;
Gullbo, Joachim ;
Richardson, Paul G. ;
Chauhan, Dharminder ;
Anderson, Kenneth C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (03) :397-409
[88]   Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma [J].
Richardson, Paul ;
Mitsiades, Constantine ;
Colson, Kathleen ;
Reilly, Eileen ;
Mcbride, Laura ;
Chiao, Judy ;
Sun, Linda ;
Ricker, Justin ;
Rizvi, Syed ;
Oerth, Carol ;
Atkins, Barbara ;
Fearen, Ivy ;
Anderson, Kenneth ;
Siegel, David .
LEUKEMIA & LYMPHOMA, 2008, 49 (03) :502-507
[89]  
Richardson PG, 2016, BLOOD, V127, P2693, DOI [10.1182/blood-2015-12686378, 10.1182/blood-2015-12-686378]
[90]   Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2Mcl-1 pathway [J].
Sadahira, Ken ;
Sagawa, Morihiko ;
Nakazato, Tomonori ;
Uchida, Hideo ;
Ikeda, Yasuo ;
Okamoto, Shinichiro ;
Nakajima, Hideaki ;
Kizaki, Masahiro .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) :2278-2286